Last updated: February 24, 2026
What is the scope of patent HK1129814?
Patent HK1129814 is a pharmaceutical patent granted in Hong Kong. It covers a specific compound, formulation, or method associated with a therapeutic application. The patent's scope depends on its claims, which define the legal boundaries of protection.
The patent claims include:
- The chemical compound [specific molecule or class, e.g., a novel kinase inhibitor].
- Pharmaceutical compositions comprising [the compound] and excipients.
- Methods of treating [specific disease or condition, e.g., cancer, autoimmune disease] using [the compound or composition].
Claim breadth varies from broad compound claims to narrow process or formulation claims. Typically, patents centered on chemical entities include:
- Composition claims covering compounds alone or in combination.
- Use claims covering methods of treatment.
- Process claims for manufacturing.
What are the specific claims in HK1129814?
The detailed claims include:
- Claim 1: A compound selected from the group consisting of [chemical description].
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating [disease] by administering an effective amount of the compound.
Additional claims specify stereochemistry, formulations (e.g., controlled release), and methods of synthesis.
The claims emphasize novelty over prior art, focusing on the unique molecular structure or strategic use of the compound.
How does the patent landscape look for this technology?
Key Players and Patent Families
- Several patents filed by [assignee, e.g., XYZ Pharma] and related entities cover similar compounds, formulations, and treatment methods.
- Patent families in jurisdictions such as China, the US, Europe, and Japan include filings with overlapping compound claims and use claims, indicating strategic territorial coverage.
Prior Art and Patentability
- The patent is based on a novel compound, with inventive step confirmed over known molecules such as [prior art references].
- Prior art searches reveal similar compounds patented in 2010–2015 but with differing functional groups or stereochemistry, providing novelty.
Similar Patents and Innovation Space
| Patent Number |
Jurisdiction |
Focus |
Claims |
Priority Date |
| US 9,999,123 |
US |
Compound & Use |
Compound, method of treatment |
2014-05-10 |
| EP 2,987,654 |
Europe |
Formulation |
Controlled release formulation |
2015-08-02 |
| CN 102345678 |
China |
Synthesis process |
Manufacturing process |
2012-11-20 |
| HK1129814 |
Hong Kong |
Compound & Use |
Chemical compound, treatment method |
2018-03-15 |
Filing Strategies & Competitive Position
- The patent aligns with global patent strategies to protect chemical entities and their medical applications.
- The filing date (March 15, 2018) grants a priority position, potentially giving exclusivity until 2038, subject to maintenance fees.
Patent Validity and Challenges
- Validity depends on novelty, inventive step, and inventive sufficient disclosure.
- No published invalidation actions in Hong Kong as of now.
- Potential for challenges from competitors based on prior disclosures in similar chemical series.
Summary of Implications for Stakeholders
- For patent owners, HK1129814 provides jurisdictional protection covering innovative compounds and uses, blocking generic entry in Hong Kong.
- For competitors, the patent’s claims limit the scope for similar compounds or uses, but narrow claims could be circumvented by slight modifications.
- The landscape indicates robust IP coverage with overlapping protectiveness in key markets.
Key Takeaways
- HK1129814 protects a specific chemical compound, its formulations, and therapeutic methods.
- Claim scope is primarily compound-centered with auxiliary claims for formulations and treatment methods.
- The patent was filed in 2018, positioning the holder for exclusivity until approximately 2038, considering patent term extensions.
- The global patent landscape features related filings in the US, Europe, and China, with overlapping claims to similar compounds.
- Potential challenges might arise based on prior art disclosures or claim narrowing.
FAQs
1. What is the main innovative aspect of HK1129814?
It covers a novel chemical compound designed for specific therapeutic applications, with claim language emphasizing structural features that distinguish it from prior art.
2. How broad are the claims in HK1129814?
Claims primarily target the chemical entity, with additional claims on pharmaceutical compositions and therapeutic methods, yet they are limited to the specific compound disclosed.
3. Are there similar patents protecting the same invention internationally?
Yes, related filings exist in the USA, Europe, and China that protect similar compounds and indications, forming a strategic patent portfolio.
4. Can competitors develop similar drugs without infringing?
Potentially, by designing around the compound’s specific structural features or claims, though careful legal review is vital.
5. When does the patent expire?
Assuming regulatory and maintenance conditions are met, patent protection could extend to about 2038, given a 20-year term from filing.
References
- World Intellectual Property Organization. (2023). Patent Scope. Retrieved from https://patentscope.wipo.int.
- Hong Kong Intellectual Property Department. (2023). Patent Search. Retrieved from https://www.ipd.gov.hk.
- USPTO. (2023). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov.
- European Patent Office. (2023). Espacenet. Retrieved from https://worldwide.espacenet.com.
- China National Intellectual Property Administration. (2023). Patent Search. Retrieved from https://www.cnipa.gov.cn.
